[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fP2iPih76GuyFE3fLcblOQKbX1jB5M9X5VNUvMwklnXQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"University of Iowa",[4],272,false,45,8,67713,19,189,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Healthy",14,{"name":18,"count":19},"Knee Osteoarthritis",10,{"name":21,"count":22},"Depression",6,{"name":24,"count":22},"Obesity",{"name":26,"count":27},"Multiple Sclerosis",5,{"name":29,"count":27},"Hypertension",{"name":31,"count":32},"Cardiovascular Diseases",4,{"name":34,"count":35},"Sedentary Lifestyle",3,[37,42,47,52,57,62,67,72,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04551040","Target Engagement of Terazosin in Healthy Adults","2023-03-01","Terazosin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04634227","Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)","2025-03-18","Ascorbate",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06499844","Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation","2025-08-12","Acetylcholine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06489249","Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use","2026-06","Salsalate 750 MG Oral Tablet [DISALCID]",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05929794","Pharmacokinetics of Transdermal Metronidazole","2026-07","Metronidazole 0.75% Topical Gel",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06559969","IV vs Epidural Opioids + Epidural Local Anesthetic for Laparotomy Analgesia","2026-12-30","Intravenous administered opioid",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05461092","Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion","2026-12-31","Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine",{"nctId":73,"briefTitle":74,"date":70,"intervention":75},"NCT04504123","MMP-9 Inhibition for Recalcitrant Wet AMD","Doxycycline Hyclate",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05169060","Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy","2027-02-01","Fish Oil Concentrate, 1000 Mg Oral",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07224269","Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis","2027-05-01","Terazosine",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,119,137,161,179,220,254,272,299,322,349,376,397,420,444,467,489,514,540,558,595,637,674,696,718,740,767,785,811,829,847,873,891,909,934,959,984,1009,1033,1057,1075,1100,1118,1143,1175,1200,1218,1242,1260,1286,1311,1336,1362,1380,1405,1430,1455,1501,1535,1573,1599,1624,1642,1667,1691,1718,1736,1761,1779,1807,1831,1853,1871,1889,1907,1925,1943,1961,1979,1997,2022,2048,2074,2092,2110,2135,2162,2188,2206,2224,2249,2274,2292,2310,2332,2354,2377,2395,2427,2445,2470,2495,2519,2537,2559,2583,2607,2631,2655,2680,2702,2726],{"intervention":61,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":117},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":60},[108],{"nctId":58,"briefTitle":59,"status":109,"phases":110,"primaryCompletion":60,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"ACTIVE_NOT_RECRUITING",[91],"2026-12","2024-02-26",24,[15],[61,116],"Metronidazole 0.75% Topical Cream",{"trials":118,"activeCount":99},[],{"intervention":116,"totalTrials":95,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":135},{"trials":122,"activeCount":99},[],{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":95,"soonestReadout":60},[131],{"nctId":58,"briefTitle":59,"status":109,"phases":132,"primaryCompletion":60,"completion":111,"start":112,"enrollment":113,"conditions":133,"interventions":134},[91],[15],[61,116],{"trials":136,"activeCount":99},[],{"intervention":66,"totalTrials":95,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":157,"NA":159},{"trials":140,"activeCount":99},[],{"trials":142,"activeCount":99},[],{"trials":144,"activeCount":99},[],{"trials":146,"activeCount":95,"soonestReadout":65},[147],{"nctId":63,"briefTitle":64,"status":148,"phases":149,"primaryCompletion":65,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},"RECRUITING",[89,90],"2027-03-30","2024-09-17",80,[154],"Laparotomy",[66,156],"Epidural administered opioid",{"trials":158,"activeCount":99},[],{"trials":160,"activeCount":99},[],{"intervention":156,"totalTrials":95,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":175,"NA":177},{"trials":164,"activeCount":99},[],{"trials":166,"activeCount":99},[],{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":95,"soonestReadout":65},[171],{"nctId":63,"briefTitle":64,"status":148,"phases":172,"primaryCompletion":65,"completion":150,"start":151,"enrollment":152,"conditions":173,"interventions":174},[89,90],[154],[66,156],{"trials":176,"activeCount":99},[],{"trials":178,"activeCount":99},[],{"intervention":180,"totalTrials":181,"cells":182},"Dostarlimab",2,{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":99},[],{"trials":188,"activeCount":95,"soonestReadout":206},[189,202],{"nctId":190,"briefTitle":191,"status":192,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":35,"conditions":197,"interventions":200},"NCT04926324","A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers","TERMINATED",[88,89],"2024-11-18","2024-12-26","2022-07-07",[198,199],"Rectal Neoplasms","Rectal Neoplasm Malignant",[201,180],"Niraparib",{"nctId":203,"briefTitle":204,"status":148,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":213},"NCT05239546","Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers",[89],"2028-06-30","2029-06-30","2023-03-24",25,[211,212],"Colon Cancer","dMMR Colorectal Cancer",[180],{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":99},[],{"intervention":221,"totalTrials":181,"cells":222},"Salsalate Oral",{"EARLY_PHASE1":223,"PHASE1":236,"PHASE2":238,"PHASE3":248,"PHASE4":250,"NA":252},{"trials":224,"activeCount":99},[225],{"nctId":226,"briefTitle":227,"status":228,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":113,"conditions":233,"interventions":235},"NCT03482440","Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia","COMPLETED",[87],"2019-07-11","2022-12-31","2018-08-26",[234],"Preeclampsia",[221],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":95,"soonestReadout":79},[240],{"nctId":77,"briefTitle":78,"status":109,"phases":241,"primaryCompletion":79,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},[88,89],"2027-07-01","2023-06-12",100,[246],"Diabetic Neuropathies",[80,221],{"trials":249,"activeCount":99},[],{"trials":251,"activeCount":99},[],{"trials":253,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":257,"activeCount":99},[],{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":95,"soonestReadout":79},[262],{"nctId":77,"briefTitle":78,"status":109,"phases":263,"primaryCompletion":79,"completion":242,"start":243,"enrollment":244,"conditions":264,"interventions":265},[88,89],[246],[80,221],{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"trials":271,"activeCount":99},[],{"intervention":273,"totalTrials":95,"cells":274},"Lutetium Lu 177 dotatate therapy",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":276,"activeCount":99},[],{"trials":278,"activeCount":99},[],{"trials":280,"activeCount":95,"soonestReadout":285},[281],{"nctId":282,"briefTitle":283,"status":148,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":292},"NCT06395402","177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry",[89],"2029-12-31","2024-05-03",120,[289,290,291],"Neuroendocrine Tumors","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2",[273],{"trials":294,"activeCount":99},[],{"trials":296,"activeCount":99},[],{"trials":298,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":302,"activeCount":99},[],{"trials":304,"activeCount":99},[],{"trials":306,"activeCount":95,"soonestReadout":70},[307],{"nctId":73,"briefTitle":74,"status":148,"phases":308,"primaryCompletion":70,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":315},[89],"2027-03-01","2020-11-04",50,[313,314],"Exudative Macular Degeneration","Wet Age-related Macular Degeneration",[75],{"trials":317,"activeCount":99},[],{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":99},[],{"intervention":323,"totalTrials":95,"cells":324},"Psilocybin",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":326,"activeCount":99},[],{"trials":328,"activeCount":99},[],{"trials":330,"activeCount":95,"soonestReadout":335},[331],{"nctId":332,"briefTitle":333,"status":148,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":152,"conditions":337,"interventions":341},"NCT06405607","Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial",[89],"2028-04","2025-06-12",[338,339,340],"Alcohol Use Disorder","Alcohol Dependence","Alcohol Abuse",[323,342],"Ketamine",{"trials":344,"activeCount":99},[],{"trials":346,"activeCount":99},[],{"trials":348,"activeCount":99},[],{"intervention":342,"totalTrials":181,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":99},[],{"trials":356,"activeCount":95,"soonestReadout":335},[357],{"nctId":332,"briefTitle":333,"status":148,"phases":358,"primaryCompletion":335,"completion":335,"start":336,"enrollment":152,"conditions":359,"interventions":360},[89],[338,339,340],[323,342],{"trials":362,"activeCount":99},[],{"trials":364,"activeCount":99},[],{"trials":366,"activeCount":99},[367],{"nctId":368,"briefTitle":369,"status":192,"phases":370,"primaryCompletion":371,"completion":371,"start":372,"enrollment":35,"conditions":373,"interventions":375},"NCT01170247","Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients",[92],"2012-01","2011-01",[374],"Sedation",[342,342],{"intervention":41,"totalTrials":95,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":95,"soonestReadout":40},[382],{"nctId":38,"briefTitle":39,"status":109,"phases":383,"primaryCompletion":40,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":388},[88],"2025-06-30","2021-03-26",18,[15],[41],{"trials":390,"activeCount":99},[],{"trials":392,"activeCount":99},[],{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":99},[],{"intervention":71,"totalTrials":95,"cells":398},{"EARLY_PHASE1":399,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":400,"activeCount":95,"soonestReadout":70},[401],{"nctId":68,"briefTitle":69,"status":148,"phases":402,"primaryCompletion":70,"completion":70,"start":403,"enrollment":311,"conditions":404,"interventions":409},[87],"2024-01-01",[405,406,407,408],"Delirium","Pain, Back","Spinal Fusion","Thoracolumbar Interfascial Plane Block",[71],{"trials":411,"activeCount":99},[],{"trials":413,"activeCount":99},[],{"trials":415,"activeCount":99},[],{"trials":417,"activeCount":99},[],{"trials":419,"activeCount":99},[],{"intervention":85,"totalTrials":95,"cells":421},{"EARLY_PHASE1":422,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":423,"activeCount":95,"soonestReadout":84},[424],{"nctId":82,"briefTitle":83,"status":425,"phases":426,"primaryCompletion":84,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":433},"NOT_YET_RECRUITING",[87],"2027-05-31","2026-05-01",20,[431,432],"Amyotrophic Lateral Sclerosis","Adenosine Triphosphate Activities",[85],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"trials":439,"activeCount":99},[],{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"intervention":56,"totalTrials":95,"cells":445},{"EARLY_PHASE1":446,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":447,"activeCount":95,"soonestReadout":55},[448],{"nctId":53,"briefTitle":54,"status":148,"phases":449,"primaryCompletion":55,"completion":450,"start":451,"enrollment":113,"conditions":452,"interventions":456},[87],"2026-10","2024-08-15",[453,454,455],"Electronic Cigarette Use","Endothelial Dysfunction","Inflammation",[56],{"trials":458,"activeCount":99},[],{"trials":460,"activeCount":99},[],{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"trials":466,"activeCount":99},[],{"intervention":51,"totalTrials":95,"cells":468},{"EARLY_PHASE1":469,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":470,"activeCount":95,"soonestReadout":50},[471],{"nctId":48,"briefTitle":49,"status":148,"phases":472,"primaryCompletion":50,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},[87],"2026-09","2024-08-01",56,[477],"Endothelial Function",[51],{"trials":480,"activeCount":99},[],{"trials":482,"activeCount":99},[],{"trials":484,"activeCount":99},[],{"trials":486,"activeCount":99},[],{"trials":488,"activeCount":99},[],{"intervention":46,"totalTrials":95,"cells":490},{"EARLY_PHASE1":491,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":492,"activeCount":95,"soonestReadout":45},[493],{"nctId":43,"briefTitle":44,"status":109,"phases":494,"primaryCompletion":45,"completion":70,"start":495,"enrollment":496,"conditions":497,"interventions":503},[87],"2020-11-24",30,[498,499,500,501,502],"Sarcoma","Soft Tissue Sarcoma","Unresectable Soft Tissue Sarcoma","Metastatic Bone Tumor","Bone Sarcoma",[46],{"trials":505,"activeCount":99},[],{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":99},[],{"trials":513,"activeCount":99},[],{"intervention":515,"totalTrials":95,"cells":516},"IV adenosine",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":99},[],{"trials":524,"activeCount":99},[],{"trials":526,"activeCount":99},[],{"trials":528,"activeCount":95,"soonestReadout":533},[529],{"nctId":530,"briefTitle":531,"status":148,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":429,"conditions":536,"interventions":538},"NCT07086560","PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department",[],"2027-06","2027-12","2025-04-04",[537],"Supraventricular Tachycardia (SVT)",[515,539],"IV diltiazem",{"intervention":539,"totalTrials":95,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":99},[],{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":95,"soonestReadout":533},[554],{"nctId":530,"briefTitle":531,"status":148,"phases":555,"primaryCompletion":533,"completion":534,"start":535,"enrollment":429,"conditions":556,"interventions":557},[],[537],[515,539],{"intervention":559,"totalTrials":181,"cells":560},"Hydrochlorothiazide",{"EARLY_PHASE1":561,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":593},{"trials":562,"activeCount":99},[563],{"nctId":564,"briefTitle":565,"status":228,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":244,"conditions":569,"interventions":572},"NCT04423627","Sympathetic Regulation of Large Artery Stiffness in Humans With ISH",[87],"2025-07-31","2021-06-01",[570,571],"Hypertension, Systolic","Stiffness, Aortic",[573,559],"Clonidine",{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":99},[],{"trials":579,"activeCount":99},[],{"trials":581,"activeCount":99},[582],{"nctId":583,"briefTitle":584,"status":192,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT03109795","Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System",[91],"2023-06-30","2017-04-10",35,[590,29],"Anxiety",[592,559],"Clonidine Pill",{"trials":594,"activeCount":99},[],{"intervention":596,"totalTrials":181,"cells":597},"Dexamethasone",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":621,"PHASE4":623,"NA":635},{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[604],{"nctId":605,"briefTitle":606,"status":192,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":611,"interventions":613},"NCT01548573","Tandem Auto Transplantation in Myeloma Patients With \u003C12 Months of Prior Treatment",[89],"2013-07","2014-08","2012-05",[612],"Multiple Myeloma",[596,614,615,616,617,618,619,620],"Cisplatin","Doxorubicin","Cyclophosphamide","Etoposide","Bortezomib","Thalidomide","Melphalan",{"trials":622,"activeCount":99},[],{"trials":624,"activeCount":99},[625],{"nctId":626,"briefTitle":627,"status":228,"phases":628,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT01868633","Dexamethasone for Post Cesarean Delivery Analgesia",[91],"2015-05","2013-03",52,[633],"Postoperative Pain",[596],{"trials":636,"activeCount":99},[],{"intervention":638,"totalTrials":181,"cells":639},"Ropivacaine",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":672},{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":99},[],{"trials":647,"activeCount":99},[],{"trials":649,"activeCount":99},[650,663],{"nctId":651,"briefTitle":652,"status":228,"phases":653,"primaryCompletion":654,"completion":654,"start":629,"enrollment":655,"conditions":656,"interventions":659},"NCT02793947","Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures",[91],"2016-08",102,[657,658],"Pain, Postoperative","Femur Fracture",[638,660,661,662],"Epinephrine","Morphine","0.9% sodium chloride solution",{"nctId":664,"briefTitle":665,"status":228,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":244,"conditions":669,"interventions":671},"NCT02967172","Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures",[91],"2018-09-21","2016-10",[657,670],"Ankle Fractures",[638,660,661,662],{"trials":673,"activeCount":99},[],{"intervention":660,"totalTrials":181,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":694},{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[686,690],{"nctId":651,"briefTitle":652,"status":228,"phases":687,"primaryCompletion":654,"completion":654,"start":629,"enrollment":655,"conditions":688,"interventions":689},[91],[657,658],[638,660,661,662],{"nctId":664,"briefTitle":665,"status":228,"phases":691,"primaryCompletion":667,"completion":667,"start":668,"enrollment":244,"conditions":692,"interventions":693},[91],[657,670],[638,660,661,662],{"trials":695,"activeCount":99},[],{"intervention":661,"totalTrials":181,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":716},{"trials":699,"activeCount":99},[],{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[708,712],{"nctId":651,"briefTitle":652,"status":228,"phases":709,"primaryCompletion":654,"completion":654,"start":629,"enrollment":655,"conditions":710,"interventions":711},[91],[657,658],[638,660,661,662],{"nctId":664,"briefTitle":665,"status":228,"phases":713,"primaryCompletion":667,"completion":667,"start":668,"enrollment":244,"conditions":714,"interventions":715},[91],[657,670],[638,660,661,662],{"trials":717,"activeCount":99},[],{"intervention":662,"totalTrials":181,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":738},{"trials":721,"activeCount":99},[],{"trials":723,"activeCount":99},[],{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[],{"trials":729,"activeCount":99},[730,734],{"nctId":651,"briefTitle":652,"status":228,"phases":731,"primaryCompletion":654,"completion":654,"start":629,"enrollment":655,"conditions":732,"interventions":733},[91],[657,658],[638,660,661,662],{"nctId":664,"briefTitle":665,"status":228,"phases":735,"primaryCompletion":667,"completion":667,"start":668,"enrollment":244,"conditions":736,"interventions":737},[91],[657,670],[638,660,661,662],{"trials":739,"activeCount":99},[],{"intervention":741,"totalTrials":95,"cells":742},"Donepezil",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":765},{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[753],{"nctId":754,"briefTitle":755,"status":228,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":763},"NCT00042172","Treatment for Early Memory Loss",[91],"2004-09","2002-06",40,[761,762],"Cognition Disorders","Alzheimer Disease",[741,764],"Ginkgo Biloba Extract",{"trials":766,"activeCount":99},[],{"intervention":764,"totalTrials":95,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":783},{"trials":770,"activeCount":99},[],{"trials":772,"activeCount":99},[],{"trials":774,"activeCount":99},[],{"trials":776,"activeCount":99},[],{"trials":778,"activeCount":99},[779],{"nctId":754,"briefTitle":755,"status":228,"phases":780,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":781,"interventions":782},[91],[761,762],[741,764],{"trials":784,"activeCount":99},[],{"intervention":786,"totalTrials":95,"cells":787},"Group A - test:Tooth extraction and intake of NSAID and a non-NSAID",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":809},{"trials":789,"activeCount":99},[],{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[798],{"nctId":799,"briefTitle":800,"status":801,"phases":802,"primaryCompletion":803,"completion":803,"start":803,"enrollment":99,"conditions":804,"interventions":806},"NCT03911336","Harnessing Chronomodulation to Enhance Osteogenesis","WITHDRAWN",[91],"2023-01-01",[805],"Tooth Loss",[786,807,808],"Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID","Group C - Control 2: tooth extraction and intake of a Non-Nsaid",{"trials":810,"activeCount":99},[],{"intervention":807,"totalTrials":95,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":827},{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":99},[],{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[823],{"nctId":799,"briefTitle":800,"status":801,"phases":824,"primaryCompletion":803,"completion":803,"start":803,"enrollment":99,"conditions":825,"interventions":826},[91],[805],[786,807,808],{"trials":828,"activeCount":99},[],{"intervention":808,"totalTrials":95,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":845},{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[841],{"nctId":799,"briefTitle":800,"status":801,"phases":842,"primaryCompletion":803,"completion":803,"start":803,"enrollment":99,"conditions":843,"interventions":844},[91],[805],[786,807,808],{"trials":846,"activeCount":99},[],{"intervention":848,"totalTrials":95,"cells":849},"Intermediate dose thromboprophylaxis",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":871},{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":99},[],{"trials":859,"activeCount":99},[860],{"nctId":861,"briefTitle":862,"status":228,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT04360824","Covid-19 Associated Coagulopathy",[91],"2021-04-16","2020-05-06",176,[868],"COVID 19 Associated Coagulopathy",[848,870],"Standard of Care thromboprophylaxis",{"trials":872,"activeCount":99},[],{"intervention":870,"totalTrials":95,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":883,"NA":889},{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"trials":882,"activeCount":99},[],{"trials":884,"activeCount":99},[885],{"nctId":861,"briefTitle":862,"status":228,"phases":886,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":887,"interventions":888},[91],[868],[848,870],{"trials":890,"activeCount":99},[],{"intervention":592,"totalTrials":95,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":907},{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[],{"trials":900,"activeCount":99},[],{"trials":902,"activeCount":99},[903],{"nctId":583,"briefTitle":584,"status":192,"phases":904,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":905,"interventions":906},[91],[590,29],[592,559],{"trials":908,"activeCount":99},[],{"intervention":910,"totalTrials":95,"cells":911},"acamprosate",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":932},{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[],{"trials":919,"activeCount":99},[],{"trials":921,"activeCount":99},[922],{"nctId":923,"briefTitle":924,"status":228,"phases":925,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT00571103","Acamprosate in the Treatment of Pathological Gambling",[91],"2009-07","2007-10",26,[930],"Pathological Gambling",[910],{"trials":933,"activeCount":99},[],{"intervention":935,"totalTrials":95,"cells":936},"Pregabalin 75mg",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":957},{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[947],{"nctId":948,"briefTitle":949,"status":192,"phases":950,"primaryCompletion":951,"completion":951,"start":952,"enrollment":429,"conditions":953,"interventions":956},"NCT05460871","Pregabalin for Central Sensitization in TKA",[91],"2024-01-25","2023-02-21",[954,955],"Osteo Arthritis Knee","Central Nervous System Sensitization",[935],{"trials":958,"activeCount":99},[],{"intervention":960,"totalTrials":95,"cells":961},"daclizumab, infliximab",{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":970,"NA":982},{"trials":963,"activeCount":99},[],{"trials":965,"activeCount":99},[],{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":99},[],{"trials":971,"activeCount":99},[972],{"nctId":973,"briefTitle":974,"status":228,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":35,"conditions":979,"interventions":981},"NCT00574470","Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD",[91],"2007-11","2008-08","2006-01",[980],"Graft vs Host Disease",[960],{"trials":983,"activeCount":99},[],{"intervention":985,"totalTrials":95,"cells":986},"intranasal povidone-iodine",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":1007},{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[997],{"nctId":998,"briefTitle":999,"status":228,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT04146116","Nasal Decolonization for Orthopedic Trauma Patients",[91],"2021-06-08","2020-02-19",65,[1005],"Surgical Site Infection",[985],{"trials":1008,"activeCount":99},[],{"intervention":1010,"totalTrials":95,"cells":1011},"Acellular Dermal Matrix",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1031},{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[1022],{"nctId":1023,"briefTitle":1024,"status":228,"phases":1025,"primaryCompletion":1026,"completion":1026,"start":1027,"enrollment":429,"conditions":1028,"interventions":1030},"NCT02450383","Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness",[91],"2016-09","2015-01",[805,1029],"Peri-implant Mucosa Defect",[1010],{"trials":1032,"activeCount":99},[],{"intervention":1034,"totalTrials":95,"cells":1035},"Nitrofurantoin monohydrate\u002Fmacrocrystals 100 mg BID x 3 days",{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1044,"NA":1055},{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":99},[],{"trials":1045,"activeCount":99},[1046],{"nctId":1047,"briefTitle":1048,"status":228,"phases":1049,"primaryCompletion":371,"completion":371,"start":1050,"enrollment":588,"conditions":1051,"interventions":1053},"NCT01749605","A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department",[91],"2010-10",[1052],"Uncomplicated Bacterial Cystitis",[1034,1054],"ciprofloxacin 250 mg BID x 3 days",{"trials":1056,"activeCount":99},[],{"intervention":1054,"totalTrials":95,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1065,"PHASE4":1067,"NA":1073},{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":99},[],{"trials":1066,"activeCount":99},[],{"trials":1068,"activeCount":99},[1069],{"nctId":1047,"briefTitle":1048,"status":228,"phases":1070,"primaryCompletion":371,"completion":371,"start":1050,"enrollment":588,"conditions":1071,"interventions":1072},[91],[1052],[1034,1054],{"trials":1074,"activeCount":99},[],{"intervention":1076,"totalTrials":95,"cells":1077},"Transderm Scop®",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1098},{"trials":1079,"activeCount":99},[],{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[1088],{"nctId":1089,"briefTitle":1090,"status":228,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":928,"conditions":1095,"interventions":1096},"NCT03029650","Scopolamine Patch Pharmacokinetics in Healthy Adults",[91],"2017-04","2018-03","2016-11",[15],[1076,1097],"Intravenous scopolamine hydrobromide",{"trials":1099,"activeCount":99},[],{"intervention":1097,"totalTrials":95,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1116},{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[1112],{"nctId":1089,"briefTitle":1090,"status":228,"phases":1113,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":928,"conditions":1114,"interventions":1115},[91],[15],[1076,1097],{"trials":1117,"activeCount":99},[],{"intervention":1119,"totalTrials":95,"cells":1120},"Povidone Iodine 5% Soln,Top,Kit",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1141},{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[1131],{"nctId":1132,"briefTitle":1133,"status":801,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":99,"conditions":1138,"interventions":1140},"NCT05745467","Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2",[91],"2025-07-01","2026-04-01","2024-07-03",[1139],"SARS-CoV-2 Acute Respiratory Disease",[1119],{"trials":1142,"activeCount":99},[],{"intervention":1144,"totalTrials":95,"cells":1145},"Refresh Plus Preservative-free Lubricant Eye Drops",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1173},{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[1156],{"nctId":1157,"briefTitle":1158,"status":228,"phases":1159,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1172},"NCT05832996","Cool vs Room-temperature Artificial Tears",[91],"2022-07-01","2022-07-06","2022-03-01",124,[1165,1166,1167,1168,1169,1170,1171],"Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis)","Central Retinal Vein Occlusion With Macular Edema","Exudative Age-Related Macular Degeneration, Unspecified Eye","Cystoid Macular Edema","Ocular Surface Disease","Dry Eye Sensation","Eye Pain",[1144],{"trials":1174,"activeCount":99},[],{"intervention":1176,"totalTrials":95,"cells":1177},"Omalizumab",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1198},{"trials":1179,"activeCount":99},[],{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[1188],{"nctId":1189,"briefTitle":1190,"status":228,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":181,"conditions":1194,"interventions":1196},"NCT00472030","Efficacy and Safety of Omalizumab in Bullous Pemphigoid",[91],"2010-12","2007-08",[1195],"Bullous Pemphigoid",[1176,1197],"prednisone",{"trials":1199,"activeCount":99},[],{"intervention":1197,"totalTrials":95,"cells":1201},{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1216},{"trials":1203,"activeCount":99},[],{"trials":1205,"activeCount":99},[],{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[1212],{"nctId":1189,"briefTitle":1190,"status":228,"phases":1213,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":181,"conditions":1214,"interventions":1215},[91],[1195],[1176,1197],{"trials":1217,"activeCount":99},[],{"intervention":1219,"totalTrials":95,"cells":1220},"Dexilant",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1240},{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[],{"trials":1226,"activeCount":99},[],{"trials":1228,"activeCount":99},[],{"trials":1230,"activeCount":99},[1231],{"nctId":1232,"briefTitle":1233,"status":801,"phases":1234,"enrollment":99,"conditions":1235,"interventions":1238},"NCT01637571","Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain",[91],[1236,1237],"Chest Pain","Gastrointestinal Reflux Disease",[1219,1239],"Dexilant Placebo",{"trials":1241,"activeCount":99},[],{"intervention":1239,"totalTrials":95,"cells":1243},{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1252,"NA":1258},{"trials":1245,"activeCount":99},[],{"trials":1247,"activeCount":99},[],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[1254],{"nctId":1232,"briefTitle":1233,"status":801,"phases":1255,"enrollment":99,"conditions":1256,"interventions":1257},[91],[1236,1237],[1219,1239],{"trials":1259,"activeCount":99},[],{"intervention":1261,"totalTrials":95,"cells":1262},"Indocyanine Green",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1271,"NA":1284},{"trials":1264,"activeCount":99},[],{"trials":1266,"activeCount":99},[],{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"trials":1272,"activeCount":99},[1273],{"nctId":1274,"briefTitle":1275,"status":228,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1283},"NCT03584633","Effect of Exercise on Indocyanine Green (ICG) Lymphography Imaging",[91],"2019-09-30","2019-12-31","2019-04-15",9,[1282],"Lymphedema",[1261],{"trials":1285,"activeCount":99},[],{"intervention":1287,"totalTrials":95,"cells":1288},"Aripiprazole",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1297,"NA":1309},{"trials":1290,"activeCount":99},[],{"trials":1292,"activeCount":99},[],{"trials":1294,"activeCount":99},[],{"trials":1296,"activeCount":99},[],{"trials":1298,"activeCount":99},[1299],{"nctId":1300,"briefTitle":1301,"status":228,"phases":1302,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1308},"NCT00250705","Trial of Aripiprazole in the Treatment of CD in Adolescents",[91],"2009-03-23","2004-11-17",12,[1307],"Conduct Disorder",[1287],{"trials":1310,"activeCount":99},[],{"intervention":1312,"totalTrials":95,"cells":1313},"Phenytoin",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1334},{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"trials":1319,"activeCount":99},[],{"trials":1321,"activeCount":99},[],{"trials":1323,"activeCount":99},[1324],{"nctId":1325,"briefTitle":1326,"status":228,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":429,"conditions":1330,"interventions":1333},"NCT00581893","Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study",[91],"2008-12","2005-08",[1331,1332],"Cognitive Measures","Driving Simulator Performance",[1312],{"trials":1335,"activeCount":99},[],{"intervention":1337,"totalTrials":95,"cells":1338},"Propofol",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1358,"NA":1360},{"trials":1340,"activeCount":99},[],{"trials":1342,"activeCount":99},[],{"trials":1344,"activeCount":99},[],{"trials":1346,"activeCount":99},[1347],{"nctId":1348,"briefTitle":1349,"status":801,"phases":1350,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":99,"conditions":1353,"interventions":1356},"NCT06756971","DISE in Pediatric Sleep Disordered Breathing",[89,90],"2023-11","2022-06-01",[1354,1355],"Sleep Disordered Breathing","Drug Induced Sleep Disorder",[1337,1357],"Dexmedetomidine",{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"intervention":1357,"totalTrials":95,"cells":1363},{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1376,"NA":1378},{"trials":1365,"activeCount":99},[],{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[],{"trials":1371,"activeCount":99},[1372],{"nctId":1348,"briefTitle":1349,"status":801,"phases":1373,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":99,"conditions":1374,"interventions":1375},[89,90],[1354,1355],[1337,1357],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"intervention":1381,"totalTrials":95,"cells":1382},"picibanil",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1401,"NA":1403},{"trials":1384,"activeCount":99},[],{"trials":1386,"activeCount":99},[],{"trials":1388,"activeCount":99},[],{"trials":1390,"activeCount":99},[1391],{"nctId":1392,"briefTitle":1393,"status":228,"phases":1394,"primaryCompletion":1395,"completion":976,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1400},"NCT00010452","Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations",[89,90],"2006-06","2000-04",150,[1399],"Lymphatic Malformations",[1381],{"trials":1402,"activeCount":99},[],{"trials":1404,"activeCount":99},[],{"intervention":1406,"totalTrials":95,"cells":1407},"Folic acid: 4 mg versus 0.4 mg per day",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1426,"NA":1428},{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[],{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":99},[1416],{"nctId":1417,"briefTitle":1418,"status":228,"phases":1419,"primaryCompletion":610,"completion":608,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1425},"NCT00397917","Oral Cleft Prevention Program",[90],"2006-11",4000,[1423,1424],"Cleft Lip","Cleft Palate",[1406],{"trials":1427,"activeCount":99},[],{"trials":1429,"activeCount":99},[],{"intervention":1431,"totalTrials":95,"cells":1432},"Citalopram",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1451,"NA":1453},{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":99},[],{"trials":1440,"activeCount":99},[1441],{"nctId":1442,"briefTitle":1443,"status":228,"phases":1444,"primaryCompletion":1445,"completion":977,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1450},"NCT00044798","Magnetic Stimulation Therapy for Treating Vascular Depression",[90],"2007-03","2001-09",132,[1449,21],"Depressive Disorder",[1431],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[],{"intervention":1456,"totalTrials":35,"cells":1457},"Nelfinavir",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1474,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":99},[1462],{"nctId":1463,"briefTitle":1464,"status":192,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT01086332","Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer",[88],"2011-07","2015-07","2009-05",7,[1471],"Pancreatic Neoplasms",[1456,1473],"Gemcitabine",{"trials":1475,"activeCount":99},[1476,1487],{"nctId":1477,"briefTitle":1478,"status":228,"phases":1479,"primaryCompletion":629,"completion":1480,"start":1481,"enrollment":1482,"conditions":1483,"interventions":1486},"NCT01065844","Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck",[89],"2017-11","2009-10",15,[1484,1485],"Carcinoma, Adenoid Cystic","Head and Neck Neoplasms",[1456],{"nctId":1488,"briefTitle":1489,"status":192,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":977,"enrollment":95,"conditions":1492,"interventions":1494},"NCT00791336","Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer",[89],"2011-03",[1493],"Carcinoma, Non-Small-Cell Lung",[1456],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[],{"intervention":1502,"totalTrials":181,"cells":1503},"Celecoxib",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1518,"PHASE3":1529,"PHASE4":1531,"NA":1533},{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[1508],{"nctId":1509,"briefTitle":1510,"status":228,"phases":1511,"primaryCompletion":1512,"completion":1094,"start":629,"enrollment":95,"conditions":1513,"interventions":1515},"NCT02401295","ATRA, Celecoxib, and Itraconazole as Maintenance",[88],"2015-08",[1514],"Relapsed Multiple Myeloma",[1516,1502,1517],"ATRA","Itraconazole",{"trials":1519,"activeCount":99},[1520],{"nctId":1521,"briefTitle":1522,"status":228,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":927,"enrollment":386,"conditions":1526,"interventions":1528},"NCT00583453","Celecoxib as a Post-tonsillectomy Pain Medication",[89],"2013-12","2016-05",[1527],"Tonsillitis",[1502],{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"intervention":1536,"totalTrials":181,"cells":1537},"Lovastatin",{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":99},[1544,1556],{"nctId":1545,"briefTitle":1546,"status":192,"phases":1547,"primaryCompletion":1548,"completion":1549,"start":1550,"enrollment":1551,"conditions":1552,"interventions":1554},"NCT00585052","A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer",[89],"2010-02","2013-06","2003-08",11,[1553],"Ovarian Cancer",[1555,1536],"Paclitaxel",{"nctId":1557,"briefTitle":1558,"status":192,"phases":1559,"primaryCompletion":1560,"completion":1549,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1565},"NCT00583102","Dose Escalation Phase I\u002FII Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML",[88,89],"2013-02","2001-06",23,[1564],"Acute Myeloid Leukemia",[1566,1536],"Cytarabine",{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"trials":1572,"activeCount":99},[],{"intervention":1574,"totalTrials":95,"cells":1575},"Temozolomide, Decitabine, Panobinostat",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[1582],{"nctId":1583,"briefTitle":1584,"status":192,"phases":1585,"primaryCompletion":1586,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1592},"NCT00925132","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",[88,89],"2014-11","2016-12","2009-12",39,[1591],"Metastatic Melanoma",[1574],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[],{"intervention":1600,"totalTrials":95,"cells":1601},"Zinc",{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"trials":1607,"activeCount":99},[1608],{"nctId":1609,"briefTitle":1610,"status":228,"phases":1611,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1617},"NCT00683644","Zinc to Treat Tinnitus in the Elderly",[89],"2011-12","2008-01",116,[1616],"Tinnitus",[1600],{"trials":1619,"activeCount":99},[],{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[],{"intervention":201,"totalTrials":95,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1636,"PHASE4":1638,"NA":1640},{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[1632],{"nctId":190,"briefTitle":191,"status":192,"phases":1633,"primaryCompletion":194,"completion":195,"start":196,"enrollment":35,"conditions":1634,"interventions":1635},[88,89],[198,199],[201,180],{"trials":1637,"activeCount":99},[],{"trials":1639,"activeCount":99},[],{"trials":1641,"activeCount":99},[],{"intervention":1643,"totalTrials":95,"cells":1644},"Retinoic Acid",{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":99},[1651],{"nctId":1652,"briefTitle":1653,"status":801,"phases":1654,"primaryCompletion":1655,"completion":1655,"start":1656,"enrollment":99,"conditions":1657,"interventions":1660},"NCT01048086","90Y DOTA\u002FRetinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)",[89],"2013-11","2009-06",[1658,1659],"Neuroblastoma","Neuroendocrine Tumor",[1643],{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"trials":1666,"activeCount":99},[],{"intervention":1668,"totalTrials":95,"cells":1669},"Talimogene Laherparepvec",{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1671,"activeCount":99},[],{"trials":1673,"activeCount":99},[],{"trials":1675,"activeCount":99},[1676],{"nctId":1677,"briefTitle":1678,"status":228,"phases":1679,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":496,"conditions":1683,"interventions":1684},"NCT02453191","TVEC and Preop Radiation for Sarcoma (4 ml Dose)",[88,89],"2019-01-22","2023-03-10","2015-07-13",[499],[1668],{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"intervention":1692,"totalTrials":95,"cells":1693},"Pentoxifylline",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1712,"PHASE4":1714,"NA":1716},{"trials":1695,"activeCount":99},[],{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[1700],{"nctId":1701,"briefTitle":1702,"status":228,"phases":1703,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":1707,"conditions":1708,"interventions":1710},"NCT00583700","Trental & Vitamin E for Radiation-Induced Fibrosis",[89],"2010-05","2012-06","2003-02",54,[1709],"Fibrosis",[1692,1711],"Vitamin E",{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[],{"intervention":1711,"totalTrials":95,"cells":1719},{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[1726],{"nctId":1701,"briefTitle":1702,"status":228,"phases":1727,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":1707,"conditions":1728,"interventions":1729},[89],[1709],[1692,1711],{"trials":1731,"activeCount":99},[],{"trials":1733,"activeCount":99},[],{"trials":1735,"activeCount":99},[],{"intervention":1737,"totalTrials":95,"cells":1738},"Tirofiban Hydrochloride",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[1745],{"nctId":1746,"briefTitle":1747,"status":801,"phases":1748,"primaryCompletion":1749,"completion":1750,"start":40,"enrollment":99,"conditions":1751,"interventions":1754},"NCT04818944","Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke",[88,89],"2025-01-01","2025-09-01",[1752,1753],"Acute Ischemic Stroke","Ischemic Stroke",[1737],{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":99},[],{"intervention":1555,"totalTrials":95,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[1769],{"nctId":1545,"briefTitle":1546,"status":192,"phases":1770,"primaryCompletion":1548,"completion":1549,"start":1550,"enrollment":1551,"conditions":1771,"interventions":1772},[89],[1553],[1555,1536],{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[],{"intervention":1780,"totalTrials":95,"cells":1781},"20mg daily citalopram",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1801,"PHASE4":1803,"NA":1805},{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[1788],{"nctId":1789,"briefTitle":1790,"status":228,"phases":1791,"primaryCompletion":1792,"completion":1793,"start":1794,"enrollment":1795,"conditions":1796,"interventions":1800},"NCT00271596","Citalopram to Enhance Cognition in HD",[89],"2011-04","2011-11","2005-11",33,[1797,1798,1799],"Huntington Disease","Chorea","Executive Dysfunction",[1780],{"trials":1802,"activeCount":99},[],{"trials":1804,"activeCount":99},[],{"trials":1806,"activeCount":99},[],{"intervention":1808,"totalTrials":95,"cells":1809},"Bethanechol",{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1814,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"trials":1815,"activeCount":99},[1816],{"nctId":1817,"briefTitle":1818,"status":192,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":181,"conditions":1822,"interventions":1824},"NCT02058537","Bethanechol for Eosinophilic Esophagitis",[89],"2014-07","2014-02",[1823],"Eosinophilic Esophagitis (EoE)",[1808],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[],{"trials":1830,"activeCount":99},[],{"intervention":1832,"totalTrials":95,"cells":1833},"atomoxetine",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[1840],{"nctId":1841,"briefTitle":1842,"status":228,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1794,"enrollment":429,"conditions":1845,"interventions":1846},"NCT00368849","Atomoxetine and Huntington's Disease",[89],"2008-02",[1797,1798],[1832],{"trials":1848,"activeCount":99},[],{"trials":1850,"activeCount":99},[],{"trials":1852,"activeCount":99},[],{"intervention":1566,"totalTrials":95,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[1861],{"nctId":1557,"briefTitle":1558,"status":192,"phases":1862,"primaryCompletion":1560,"completion":1549,"start":1561,"enrollment":1562,"conditions":1863,"interventions":1864},[88,89],[1564],[1566,1536],{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[],{"trials":1870,"activeCount":99},[],{"intervention":614,"totalTrials":95,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[1879],{"nctId":605,"briefTitle":606,"status":192,"phases":1880,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1881,"interventions":1882},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[],{"intervention":615,"totalTrials":95,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":99},[],{"trials":1894,"activeCount":99},[],{"trials":1896,"activeCount":99},[1897],{"nctId":605,"briefTitle":606,"status":192,"phases":1898,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1899,"interventions":1900},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"intervention":616,"totalTrials":95,"cells":1908},{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[],{"trials":1914,"activeCount":99},[1915],{"nctId":605,"briefTitle":606,"status":192,"phases":1916,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1917,"interventions":1918},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"intervention":617,"totalTrials":95,"cells":1926},{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1928,"activeCount":99},[],{"trials":1930,"activeCount":99},[],{"trials":1932,"activeCount":99},[1933],{"nctId":605,"briefTitle":606,"status":192,"phases":1934,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1935,"interventions":1936},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1938,"activeCount":99},[],{"trials":1940,"activeCount":99},[],{"trials":1942,"activeCount":99},[],{"intervention":618,"totalTrials":95,"cells":1944},{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"trials":1950,"activeCount":99},[1951],{"nctId":605,"briefTitle":606,"status":192,"phases":1952,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1953,"interventions":1954},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1956,"activeCount":99},[],{"trials":1958,"activeCount":99},[],{"trials":1960,"activeCount":99},[],{"intervention":619,"totalTrials":95,"cells":1962},{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1964,"activeCount":99},[],{"trials":1966,"activeCount":99},[],{"trials":1968,"activeCount":99},[1969],{"nctId":605,"briefTitle":606,"status":192,"phases":1970,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1971,"interventions":1972},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1974,"activeCount":99},[],{"trials":1976,"activeCount":99},[],{"trials":1978,"activeCount":99},[],{"intervention":620,"totalTrials":95,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1982,"activeCount":99},[],{"trials":1984,"activeCount":99},[],{"trials":1986,"activeCount":99},[1987],{"nctId":605,"briefTitle":606,"status":192,"phases":1988,"primaryCompletion":608,"completion":609,"start":610,"enrollment":11,"conditions":1989,"interventions":1990},[89],[612],[596,614,615,616,617,618,619,620],{"trials":1992,"activeCount":99},[],{"trials":1994,"activeCount":99},[],{"trials":1996,"activeCount":99},[],{"intervention":1998,"totalTrials":95,"cells":1999},"[F18]Fluorothymidine",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2016,"PHASE4":2018,"NA":2020},{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[2006],{"nctId":2007,"briefTitle":2008,"status":192,"phases":2009,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":22,"conditions":2013,"interventions":2015},"NCT01075412","FLT PET Imaging for Cervical Cancer",[89],"2016-03-03","2016-04-11","2009-09",[2014],"Uterine Cervical Neoplasms",[1998],{"trials":2017,"activeCount":99},[],{"trials":2019,"activeCount":99},[],{"trials":2021,"activeCount":99},[],{"intervention":2023,"totalTrials":95,"cells":2024},"18F-Fluorothymidine PET scan",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[2031],{"nctId":2032,"briefTitle":2033,"status":228,"phases":2034,"primaryCompletion":2035,"completion":2035,"start":2036,"enrollment":1795,"conditions":2037,"interventions":2041},"NCT00721799","F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients",[89],"2014-12-31","2008-03-01",[2038,2039,2040,1485],"Mouth Neoplasms","Oropharyngeal Neoplasms","Laryngeal Neoplasms",[2023],{"trials":2043,"activeCount":99},[],{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"intervention":2049,"totalTrials":95,"cells":2050},"Docetaxel",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2068,"PHASE4":2070,"NA":2072},{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[2057],{"nctId":2058,"briefTitle":2059,"status":192,"phases":2060,"primaryCompletion":2061,"completion":2062,"start":1420,"enrollment":181,"conditions":2063,"interventions":2065},"NCT00426127","Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer",[89],"2009-01","2009-08",[2064],"Pancreatic Cancer",[2049,2066,2067],"Liposomal Doxorubicin","Enoxaparin",{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":99},[],{"intervention":2066,"totalTrials":95,"cells":2075},{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2077,"activeCount":99},[],{"trials":2079,"activeCount":99},[],{"trials":2081,"activeCount":99},[2082],{"nctId":2058,"briefTitle":2059,"status":192,"phases":2083,"primaryCompletion":2061,"completion":2062,"start":1420,"enrollment":181,"conditions":2084,"interventions":2085},[89],[2064],[2049,2066,2067],{"trials":2087,"activeCount":99},[],{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"intervention":2067,"totalTrials":95,"cells":2093},{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[2100],{"nctId":2058,"briefTitle":2059,"status":192,"phases":2101,"primaryCompletion":2061,"completion":2062,"start":1420,"enrollment":181,"conditions":2102,"interventions":2103},[89],[2064],[2049,2066,2067],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[],{"trials":2109,"activeCount":99},[],{"intervention":2111,"totalTrials":95,"cells":2112},"Amino Acids",{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[2119],{"nctId":2120,"briefTitle":2121,"status":228,"phases":2122,"primaryCompletion":2123,"completion":2123,"start":2124,"enrollment":1589,"conditions":2125,"interventions":2128},"NCT03273712","Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)",[89],"2020-05-27","2017-09-29",[289,2126,1658,2127],"Meningioma","Medulloblastoma",[2111],{"trials":2130,"activeCount":99},[],{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"intervention":2136,"totalTrials":95,"cells":2137},"Curcumin",{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2156,"PHASE4":2158,"NA":2160},{"trials":2139,"activeCount":99},[],{"trials":2141,"activeCount":99},[],{"trials":2143,"activeCount":99},[2144],{"nctId":2145,"briefTitle":2146,"status":801,"phases":2147,"primaryCompletion":2148,"completion":2148,"start":2149,"enrollment":99,"conditions":2150,"interventions":2155},"NCT04132648","Curcumin and Exercise in Chronic Kidney Disease",[89],"2021-11-01","2020-11-15",[2151,2152,2153,2154],"Chronic Kidney Diseases","Blood Pressure","Hyperemia","Vasoconstriction",[2136],{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"intervention":2163,"totalTrials":95,"cells":2164},"Metformin",{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2166,"activeCount":99},[],{"trials":2168,"activeCount":99},[],{"trials":2170,"activeCount":99},[2171],{"nctId":2172,"briefTitle":2173,"status":192,"phases":2174,"primaryCompletion":2175,"completion":2175,"start":1491,"enrollment":2176,"conditions":2177,"interventions":2179},"NCT01351753","Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity",[89],"2014-01-09",128,[24,2178],"Metabolic Syndrome X",[2163,2180,2181],"Orlistat","Topiramate",{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[],{"intervention":2180,"totalTrials":95,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[2196],{"nctId":2172,"briefTitle":2173,"status":192,"phases":2197,"primaryCompletion":2175,"completion":2175,"start":1491,"enrollment":2176,"conditions":2198,"interventions":2199},[89],[24,2178],[2163,2180,2181],{"trials":2201,"activeCount":99},[],{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[],{"intervention":2181,"totalTrials":95,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2218,"PHASE4":2220,"NA":2222},{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[2214],{"nctId":2172,"briefTitle":2173,"status":192,"phases":2215,"primaryCompletion":2175,"completion":2175,"start":1491,"enrollment":2176,"conditions":2216,"interventions":2217},[89],[24,2178],[2163,2180,2181],{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":99},[],{"intervention":2225,"totalTrials":95,"cells":2226},"CpG 7909",{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2241,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[2231],{"nctId":2232,"briefTitle":2233,"status":228,"phases":2234,"primaryCompletion":2235,"completion":2235,"start":2236,"enrollment":2237,"conditions":2238,"interventions":2240},"NCT00233506","A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated",[88],"2011-06","2004-07",41,[2239],"Chronic Lymphocytic Leukemia",[2225],{"trials":2242,"activeCount":99},[],{"trials":2244,"activeCount":99},[],{"trials":2246,"activeCount":99},[],{"trials":2248,"activeCount":99},[],{"intervention":2250,"totalTrials":95,"cells":2251},"2-deoxyglucose",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2272},{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[2256],{"nctId":2257,"briefTitle":2258,"status":801,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":99,"conditions":2262,"interventions":2265},"NCT00247403","Safety Study of 2DG With Stereotactic Radiosurgery",[88],"2008-06","2005-10",[2263,2264],"Intracranial Neoplasms","Neoplasm Metastasis",[2250],{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[],{"intervention":1516,"totalTrials":95,"cells":2275},{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2284,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2277,"activeCount":99},[],{"trials":2279,"activeCount":99},[2280],{"nctId":1509,"briefTitle":1510,"status":228,"phases":2281,"primaryCompletion":1512,"completion":1094,"start":629,"enrollment":95,"conditions":2282,"interventions":2283},[88],[1514],[1516,1502,1517],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[],{"intervention":1517,"totalTrials":95,"cells":2293},{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2302,"PHASE3":2304,"PHASE4":2306,"NA":2308},{"trials":2295,"activeCount":99},[],{"trials":2297,"activeCount":99},[2298],{"nctId":1509,"briefTitle":1510,"status":228,"phases":2299,"primaryCompletion":1512,"completion":1094,"start":629,"enrollment":95,"conditions":2300,"interventions":2301},[88],[1514],[1516,1502,1517],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"intervention":2311,"totalTrials":95,"cells":2312},"TP10",{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2324,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2314,"activeCount":99},[],{"trials":2316,"activeCount":99},[2317],{"nctId":2318,"briefTitle":2319,"status":801,"phases":2320,"primaryCompletion":668,"completion":668,"start":1586,"enrollment":99,"conditions":2321,"interventions":2323},"NCT02302755","TP10 Use in Patients With C3 Glomerulopathy (C3G)",[88],[2322],"Dense Deposit Disease",[2311],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"intervention":2333,"totalTrials":95,"cells":2334},"Sulodexide",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2346,"PHASE3":2348,"PHASE4":2350,"NA":2352},{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[2339],{"nctId":2340,"briefTitle":2341,"status":801,"phases":2342,"primaryCompletion":1588,"completion":1588,"start":2343,"enrollment":99,"conditions":2344,"interventions":2345},"NCT00583427","Sulodexide Treatment in Patients With Dense Deposit Disease",[88],"2007-12",[2322],[2333],{"trials":2347,"activeCount":99},[],{"trials":2349,"activeCount":99},[],{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"intervention":2355,"totalTrials":95,"cells":2356},"aspirin",{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2369,"PHASE3":2371,"PHASE4":2373,"NA":2375},{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[2361],{"nctId":2362,"briefTitle":2363,"status":228,"phases":2364,"primaryCompletion":609,"completion":609,"start":2365,"enrollment":1551,"conditions":2366,"interventions":2368},"NCT01710072","Aspirin Attenuates Inflammation in Human Cerebral Aneurysms",[88],"2011-08",[2367],"The Focus of the Study is to Monitor MRI Signal Changes and Inflammatory Biomarkers With Use of Aspirin in Patients With Unruptured Cerebral Aneurysm",[2355],{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":99},[],{"intervention":1473,"totalTrials":95,"cells":2378},{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2387,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[2383],{"nctId":1463,"briefTitle":1464,"status":192,"phases":2384,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":2385,"interventions":2386},[88],[1471],[1456,1473],{"trials":2388,"activeCount":99},[],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"intervention":2396,"totalTrials":95,"cells":2397},"Durvalumab",{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2419,"PHASE3":2421,"PHASE4":2423,"NA":2425},{"trials":2399,"activeCount":99},[],{"trials":2401,"activeCount":99},[2402],{"nctId":2403,"briefTitle":2404,"status":192,"phases":2405,"primaryCompletion":2406,"completion":2406,"start":2407,"enrollment":27,"conditions":2408,"interventions":2418},"NCT04108481","Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer",[88],"2023-11-17","2020-10-05",[2409,211,2410,2411,2412,2413,2414,2415,2416,2417],"Colorectal Cancer Metastatic","Metastatic Colorectal Cancer","Rectal Cancer","Liver Metastasis Colon Cancer","Colo-rectal Cancer","Colorectal Adenocarcinoma","Colorectal Neoplasms","Liver Metastases","Colorectal Carcinoma",[2396],{"trials":2420,"activeCount":99},[],{"trials":2422,"activeCount":99},[],{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"intervention":573,"totalTrials":95,"cells":2428},{"EARLY_PHASE1":2429,"PHASE1":2435,"PHASE2":2437,"PHASE3":2439,"PHASE4":2441,"NA":2443},{"trials":2430,"activeCount":99},[2431],{"nctId":564,"briefTitle":565,"status":228,"phases":2432,"primaryCompletion":567,"completion":567,"start":568,"enrollment":244,"conditions":2433,"interventions":2434},[87],[570,571],[573,559],{"trials":2436,"activeCount":99},[],{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"intervention":2446,"totalTrials":95,"cells":2447},"(68Ga)PSMA-HBED-CC",{"EARLY_PHASE1":2448,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2449,"activeCount":99},[2450],{"nctId":2451,"briefTitle":2452,"status":228,"phases":2453,"primaryCompletion":2454,"completion":2454,"start":2455,"enrollment":2456,"conditions":2457,"interventions":2459},"NCT02952469","Biodistribution\u002FReproducibility Ga-68 PSMA-HBED-CC",[87],"2022-04-25","2016-07-14",22,[2458],"Prostatic Neoplasms",[2446],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[],{"trials":2467,"activeCount":99},[],{"trials":2469,"activeCount":99},[],{"intervention":2471,"totalTrials":95,"cells":2472},"To keep open (TKO) infusion of 0.9% normal saline",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2474,"activeCount":99},[],{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[],{"trials":2482,"activeCount":99},[],{"trials":2484,"activeCount":99},[2485],{"nctId":2486,"briefTitle":2487,"status":228,"phases":2488,"primaryCompletion":2489,"completion":2489,"start":2490,"enrollment":2491,"conditions":2492,"interventions":2494},"NCT03533777","Antegrade Versus Retrograde IV for Blood Draws",[92],"2019-06-19","2018-06-22",230,[2493],"There is no Focus on Any Specific Condition",[2471],{"intervention":2496,"totalTrials":95,"cells":2497},"Xylitol",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[],{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[2510],{"nctId":2511,"briefTitle":2512,"status":228,"phases":2513,"primaryCompletion":609,"completion":609,"start":1468,"enrollment":2514,"conditions":2515,"interventions":2517},"NCT00924404","Xylitol Versus Saline in Chronic Sinusitis",[92],53,[2516],"Chronic Sinusitis",[2496,2518],"Saline",{"intervention":2518,"totalTrials":95,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2529,"NA":2531},{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[2533],{"nctId":2511,"briefTitle":2512,"status":228,"phases":2534,"primaryCompletion":609,"completion":609,"start":1468,"enrollment":2514,"conditions":2535,"interventions":2536},[92],[2516],[2496,2518],{"intervention":2538,"totalTrials":95,"cells":2539},"Eicosapentaenoic acid (EPA) 0.7 grams\u002Fday or 1.5 grams\u002Fday",{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[2552],{"nctId":2553,"briefTitle":2554,"status":228,"phases":2555,"primaryCompletion":927,"completion":927,"start":2261,"enrollment":113,"conditions":2556,"interventions":2558},"NCT00256412","Essential Fatty Acids for Major Depression",[92],[2557],"Major Depression",[2538],{"intervention":2560,"totalTrials":95,"cells":2561},"Anecortave Acetate",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2563,"activeCount":99},[],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[],{"trials":2569,"activeCount":99},[],{"trials":2571,"activeCount":99},[],{"trials":2573,"activeCount":99},[2574],{"nctId":2575,"briefTitle":2576,"status":2577,"phases":2578,"completion":977,"start":2579,"conditions":2580,"interventions":2582},"NCT00349739","Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate","NO_LONGER_AVAILABLE",[],"2003-01",[2581],"Macular Degeneration",[2560],{"intervention":2584,"totalTrials":95,"cells":2585},"Omega-3 Acid Ethyl Esters",{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2596},{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[],{"trials":2597,"activeCount":99},[2598],{"nctId":2599,"briefTitle":2600,"status":192,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":95,"conditions":2604,"interventions":2606},"NCT01002118","Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients",[92],"2011-02-23","2008-01-25",[2605],"Cardiovascular Disease",[2584],{"intervention":2608,"totalTrials":95,"cells":2609},"heparin",{"EARLY_PHASE1":2610,"PHASE1":2612,"PHASE2":2614,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2611,"activeCount":99},[],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":99},[],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[2622],{"nctId":2623,"briefTitle":2624,"status":228,"phases":2625,"completion":2626,"start":2627,"enrollment":113,"conditions":2628,"interventions":2630},"NCT00004694","Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations",[92],"1998-09","1994-01",[2629],"Angioedema",[2608],{"intervention":2632,"totalTrials":95,"cells":2633},"Bupropion",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2640,"PHASE4":2642,"NA":2644},{"trials":2635,"activeCount":99},[],{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[2646],{"nctId":2647,"briefTitle":2648,"status":228,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":152,"conditions":2653,"interventions":2654},"NCT00055393","Bupropion in the Treatment of Pathological Gambling",[92],"2005-05","2006-04","2002-07",[930],[2632],{"intervention":2656,"totalTrials":95,"cells":2657},"Tissue Plasminogen Activator",{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2659,"activeCount":99},[],{"trials":2661,"activeCount":99},[],{"trials":2663,"activeCount":99},[],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[2670],{"nctId":2671,"briefTitle":2672,"status":228,"phases":2673,"primaryCompletion":2674,"completion":2674,"start":2675,"enrollment":2676,"conditions":2677,"interventions":2679},"NCT02752256","Thrombolytic Care During Inter-hospital Transfer",[],"2017-10","2015-10",76,[2678],"Stroke",[2656],{"intervention":2681,"totalTrials":95,"cells":2682},"Ranitidine",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2691,"NA":2693},{"trials":2684,"activeCount":99},[],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[2695],{"nctId":2696,"briefTitle":2697,"status":228,"phases":2698,"primaryCompletion":1613,"completion":1613,"start":2699,"enrollment":244,"conditions":2700,"interventions":2701},"NCT00585351","Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting",[92],"2007-01",[2678],[2681],{"intervention":2703,"totalTrials":95,"cells":2704},"Droperidol",{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2706,"activeCount":99},[],{"trials":2708,"activeCount":99},[],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":99},[2717],{"nctId":2718,"briefTitle":2719,"status":192,"phases":2720,"primaryCompletion":2721,"completion":2721,"start":1466,"enrollment":11,"conditions":2722,"interventions":2724},"NCT01406860","Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches",[92],"2012-07",[2723],"Primary Headaches (Includes Migraines, Tension, Cluster Headaches)",[2703,2725],"Metoclopramide + diphenhydramine",{"intervention":2725,"totalTrials":95,"cells":2727},{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2732,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[2740],{"nctId":2718,"briefTitle":2719,"status":192,"phases":2741,"primaryCompletion":2721,"completion":2721,"start":1466,"enrollment":11,"conditions":2742,"interventions":2743},[92],[2723],[2703,2725]]